Trial
NCT00843531
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Genentech, Inc.; Novartis Pharmaceuticals; The V Foundation for Cancer Research
Condition
Neuroendocrine Tumors
Intervention
RAD001
Why stopped
Low Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-29